Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
Why the study?
The advisory was developed to summarize the lipid and lipoprotein effects resulting from pharmacological doses of omega-3 fatty acids (>3 g/d total EPA+DHA) on the basis of new scientific data and availability of prescription agents.
Do prescription omega-3 fatty acids at a dose of 4 g/d reduce triglycerides in patients with hypertriglyceridemia?
Population
Patients with hypertriglyceridemia or very high triglycerides
Comparison
Prescription omega-3 fatty acids (EPA+DHA or EPA-only) vs other regimens
Design
American Heart Association science advisory
Authors
Discussion
Loading...
Member takes
Implication
May support triglyceride reduction with 4 g/d prescription omega-3s; leaves open cardiovascular outcome benefits and optimal formulation.
Structured PICO
Do prescription omega-3 fatty acids at a dose of 4 g/d reduce triglycerides in patients with hypertriglyceridemia?
P
Population
Patients with hypertriglyceridemia (triglycerides 200-499 mg/dL) or very high triglycerides (≥500 mg/dL)
I
Intervention
Prescription omega-3 fatty acids (EPA+DHA or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA)
O
Outcome
Triglyceride reduction and lipid/lipoprotein effectssurrogate
Prescription omega-3 fatty acids at a dose of 4 g/d are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents.
Cite This Study
Skulas‐Ray et al. (2019) studied this question.